Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

0.2350 -0.0005 (-0.21%)
Streaming Delayed Price Updated: 2:43 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 340,163
Open 0.2425
Bid (Size) 0.2349 (2)
Ask (Size) 0.2350 (5)
Prev. Close 0.2355
Today's Range 0.2317 - 0.2426
52wk Range 0.2310 - 13.88
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
Via ACCESSWIRE
Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea
Via ACCESSWIRE

Performance

YTD
-96.42%
-96.42%
1 Month
-38.80%
-38.80%
3 Month
-57.17%
-57.17%
6 Month
-61.63%
-61.63%
1 Year
-98.08%
-98.08%

More News

Read More
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
Via ACCESSWIRE
Peru's Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details
Via Benzinga
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Via ACCESSWIRE
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
Via ACCESSWIRE
Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
Via ACCESSWIRE
BioMedNewsBreaks – Jaguar Health Inc. (NASDAQ: JAGX) Announces Investor Engagement Campaign with B2i Digital
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
Via ACCESSWIRE
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Via ACCESSWIRE
Jaguar Health Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
Via ACCESSWIRE
Earnings Scheduled For August 14, 2023
Via Benzinga
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Via ACCESSWIRE
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Via ACCESSWIRE
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.